Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
AEON Biopharma Announces Execution of Exchange Agreement with Daewoong
-
AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling
-
AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth
-
AEON Biopharma Reports Positive and Robust Biosimilarity Results: Identical Amino Acid Sequence and Highly Similar Functional Analysis Data
-
AEON Biopharma Announces Fundraise Totaling Up to ~$22 Million through Private Placement and Proposed Exchange of Daewoong Convertible Notes
-
AEON Biopharma Announces FDA BPD Type 2a Meeting for ABP-450 on November 19
-
AEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update
-
SAN FRANCISCO, April 16, 2025 (GLOBE NEWSWIRE) -- Ivy En Rose, San Francisco’s premier elite MedSpa, is proud to announce an exciting partnership with the Junior League of San Francisco for an...
-
Dublin, April 14, 2025 (GLOBE NEWSWIRE) -- The "Botulinum Toxin Market - Forecasts from 2025 to 2030" report has been added to ResearchAndMarkets.com's offering.The Botulinum Toxins Market, valued...
-
SAN FRANCISCO, March 26, 2025 (GLOBE NEWSWIRE) -- Ivy En Rose, San Francisco’s premier elite MedSpa, is proud to announce an exciting partnership with the Junior League of San Francisco for an...